Conor/Novartis DES pact
This article was originally published in The Gray Sheet
Executive Summary
Three Novartis pharmaceutical compounds - imatinib mesylate, pimecrolimus and the pre-commercial compound midostaurin - will be evaluated for use with Conor's porous stent technology to treat restenosis under a March 15 agreement. Pending successful results, Conor Medsystems will be granted the option to obtain a worldwide, non-exclusive license to develop a drug-eluting stent with one of the compounds. The deal could offer Conor a back-door approach to the DES market in the event that litigation deters Conor's CoStar paclitaxel-eluting stent from becoming commercially available. Boston Scientific and Angiotech Pharmaceuticals have brought patent infringement suits against the Menlo Park, Calif. firm (1"The Gray Sheet" Feb. 7, 2005, p. 7)...
You may also be interested in...
Conor CoStar Cleared For European Launch; Firm Modifies U.S. Trial Design
Conor Medsystems will launch its CoStar paclitaxel-eluting, cobalt-chromium coronary stent in Europe, having just received a CE mark, the firm said Feb. 17
Taxus Companies Clash With Conor Over European Paclitaxel Patent
Boston Scientific and Angiotech Pharmaceuticals are attempting to block Conor Medsystems' use of clinical trial data that would support a European CE mark for the CoStar paclitaxel-eluting stent
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.